|
|
Vaccine Detail
|
Ipilimumab |
| Vaccine Information |
- Vaccine Name: Ipilimumab
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: monoclonal antibody
- Status: Research
- Antigen: cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), gp100
- Immunization Route: Intramuscular injection (i.m.)
- Description: A fully human monoclonal antibody against cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) that has been shown to improve survival in patients with pretreated, advanced melanoma in a phase III trial. Ipilimumab provided durable objective responses and/or stable disease in qualifying patients who received retreatment upon disease progression with a similar toxicity profile to that seen during their original treatment regimen (Robert et al., 2013).
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: CTLA-4 is a negative regulator of T-cells, which are known to play a critical role in the immunosurveillance and destruction of tumors. By blocking CTLA-4, ipilimumab acts to potentiate T-cell-mediated antitumor immune responses (Robert et al., 2013).
|
| References |
Robert et al., 2013: Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013; 19(8); 2232-2239. [PubMed: 23444228].
|
|
